The bill introduces the "Prescription Drug Sales Representative Disclosure Act," which requires pharmaceutical manufacturers to provide the Department of Business Regulation with a detailed and updated list of each pharmaceutical sales representative who markets prescription drugs on their behalf to healthcare providers, pharmacies, and medical facilities in the state. Manufacturers must inform the department of any changes to this list within 60 days and are required to update the list annually. A fee of $55 will be charged for each representative listed.

Additionally, the act mandates that pharmaceutical sales representatives submit an annual report by March 1, detailing any compensation, gifts, or items of value provided to healthcare providers, with specific thresholds for reporting. The report must also include the names and manufacturers of prescription drugs for which free samples were provided. The Department of Business Regulation will analyze this information and compile an annual report on the activities of pharmaceutical sales representatives, which will be posted on the department's website and submitted to various state officials.

The act prohibits any individual not included on the current list from marketing prescription drugs to healthcare providers, pharmacies, or medical facilities in the state. Non-compliance with these requirements may result in civil penalties of up to $10,000 per violation, enforceable by the Attorney General. The act is set to take effect on January 1, 2026.